Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 44 entries
Sorted by: Best Match Show Resources per page
[Not Available].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

Amadane N, Mortier P, André M, Lechevalier E.
PMID: 26544417
Prog Urol. 2015 Nov;25(13):828. doi: 10.1016/j.purol.2015.08.221.

No abstract available.

Cite
Amadane N, Mortier P, André M, et al. Prise en charge des tumeurs du rein T1a par radiofréquence. Suivi après 5 ans. [Not Available]. Prog Urol. 2015;25(13):828doi: 10.1016/j.purol.2015.08.221.
Amadane, N., Mortier, P., André, M., & Lechevalier, E. (2015). Prise en charge des tumeurs du rein T1a par radiofréquence. Suivi après 5 ans. [Not Available]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 25(13), 828. https://doi.org/10.1016/j.purol.2015.08.221
Amadane, N, et al. "Prise en charge des tumeurs du rein T1a par radiofréquence. Suivi après 5 ans." [Not Available]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie vol. 25,13 (2015): 828. doi: https://doi.org/10.1016/j.purol.2015.08.221
Amadane N, Mortier P, André M, Lechevalier E. Prise en charge des tumeurs du rein T1a par radiofréquence. Suivi après 5 ans. [Not Available]. Prog Urol. 2015 Nov;25(13):828. doi: 10.1016/j.purol.2015.08.221. French. PMID: 26544417.
Copy Download .nbib Format: NLM
Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation.

OncoTargets and therapy

Kader YA, Le Chevalier T, El-Nahas T, Sakr A.
PMID: 23836994
Onco Targets Ther. 2013 Jul 01;6:803-9. doi: 10.2147/OTT.S45906. Print 2013.

PURPOSE: The majority of Egyptian patients with lung cancer present at a late stage of the disease. Bevacizumab/carboplatin/paclitaxel, as well as cisplatin plus pemetrexed, are both standard regimens for advanced non-squamous bronchogenic cancer. This study compares both regimens, in...

Cite
Kader YA, Le Chevalier T, El-Nahas T, et al. Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation. Onco Targets Ther. 2013;6:803-9doi: 10.2147/OTT.S45906.
Kader, Y. A., Le Chevalier, T., El-Nahas, T., & Sakr, A. (2013). Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation. OncoTargets and therapy, 6803-9. https://doi.org/10.2147/OTT.S45906
Kader, Yasser Abdel, et al. "Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation." OncoTargets and therapy vol. 6 (2013): 803-9. doi: https://doi.org/10.2147/OTT.S45906
Kader YA, Le Chevalier T, El-Nahas T, Sakr A. Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation. Onco Targets Ther. 2013 Jul 01;6:803-9. doi: 10.2147/OTT.S45906. Print 2013. PMID: 23836994; PMCID: PMC3702548.
Copy Download .nbib Format: NLM
Influence of substrate types and morphological traits on movement behavior in a toad and newt species.

PeerJ

Trochet A, Le Chevalier H, Calvez O, Ribéron A, Bertrand R, Blanchet S.
PMID: 30643673
PeerJ. 2019 Jan 09;6:e6053. doi: 10.7717/peerj.6053. eCollection 2019.

BACKGROUND: Inter-patch movements may lead to genetic mixing, decreasing both inbreeding and population extinction risks, and is hence a crucial aspect of amphibian meta-population dynamics. Traveling through heterogeneous landscapes might be particularly risky for amphibians. Understanding how these species...

Cite
Trochet A, Le Chevalier H, Calvez O, et al. Influence of substrate types and morphological traits on movement behavior in a toad and newt species. PeerJ. 2019;6:e6053doi: 10.7717/peerj.6053.
Trochet, A., Le Chevalier, H., Calvez, O., Ribéron, A., Bertrand, R., & Blanchet, S. (2019). Influence of substrate types and morphological traits on movement behavior in a toad and newt species. PeerJ, 6e6053. https://doi.org/10.7717/peerj.6053
Trochet, Audrey, et al. "Influence of substrate types and morphological traits on movement behavior in a toad and newt species." PeerJ vol. 6 (2019): e6053. doi: https://doi.org/10.7717/peerj.6053
Trochet A, Le Chevalier H, Calvez O, Ribéron A, Bertrand R, Blanchet S. Influence of substrate types and morphological traits on movement behavior in a toad and newt species. PeerJ. 2019 Jan 09;6:e6053. doi: 10.7717/peerj.6053. eCollection 2019. PMID: 30643673; PMCID: PMC6330043.
Copy Download .nbib Format: NLM
An unusual case of cytoplasmic CD3 expressing BPDCN supporting the T-lineage origin of plasmacytoid dendritic cells.

Cytometry. Part B, Clinical cytometry

Brett VE, Menguy S, Arcourt A, Bidet A, Lechevalier N, Leguay T, Klein E, Garnache-Ottou F, Vial JP.
PMID: 34787365
Cytometry B Clin Cytom. 2021 Nov 17; doi: 10.1002/cyto.b.22039. Epub 2021 Nov 17.

No abstract available.

Cite
Brett VE, Menguy S, Arcourt A, et al. An unusual case of cytoplasmic CD3 expressing BPDCN supporting the T-lineage origin of plasmacytoid dendritic cells. Cytometry B Clin Cytom. 2021;doi: 10.1002/cyto.b.22039.
Brett, V. E., Menguy, S., Arcourt, A., Bidet, A., Lechevalier, N., Leguay, T., Klein, E., Garnache-Ottou, F., & Vial, J. P. (2021). An unusual case of cytoplasmic CD3 expressing BPDCN supporting the T-lineage origin of plasmacytoid dendritic cells. Cytometry. Part B, Clinical cytometry, . https://doi.org/10.1002/cyto.b.22039
Brett, Victor-Emmanuel, et al. "An unusual case of cytoplasmic CD3 expressing BPDCN supporting the T-lineage origin of plasmacytoid dendritic cells." Cytometry. Part B, Clinical cytometry vol. (2021). doi: https://doi.org/10.1002/cyto.b.22039
Brett VE, Menguy S, Arcourt A, Bidet A, Lechevalier N, Leguay T, Klein E, Garnache-Ottou F, Vial JP. An unusual case of cytoplasmic CD3 expressing BPDCN supporting the T-lineage origin of plasmacytoid dendritic cells. Cytometry B Clin Cytom. 2021 Nov 17; doi: 10.1002/cyto.b.22039. Epub 2021 Nov 17. PMID: 34787365.
Copy Download .nbib Format: NLM
Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia.

Cancers

Vial JP, Lechevalier N, Lacombe F, Dumas PY, Bidet A, Leguay T, Vergez F, Pigneux A, Béné MC.
PMID: 33562525
Cancers (Basel). 2021 Feb 05;13(4). doi: 10.3390/cancers13040629.

The assessment of minimal residual disease (MRD) is increasingly considered to monitor response to therapy in hematological malignancies. In acute myeloblastic leukemia (AML), molecular MRD (mMRD) is possible for about half the patients while multiparameter flow cytometry (MFC) is...

Cite
Vial JP, Lechevalier N, Lacombe F, et al. Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia. Cancers (Basel). 2021;13(4)doi: 10.3390/cancers13040629.
Vial, J. P., Lechevalier, N., Lacombe, F., Dumas, P. Y., Bidet, A., Leguay, T., Vergez, F., Pigneux, A., & Béné, M. C. (2021). Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia. Cancers, 13(4), . https://doi.org/10.3390/cancers13040629
Vial, Jean Philippe, et al. "Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia." Cancers vol. 13,4 (2021). doi: https://doi.org/10.3390/cancers13040629
Vial JP, Lechevalier N, Lacombe F, Dumas PY, Bidet A, Leguay T, Vergez F, Pigneux A, Béné MC. Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia. Cancers (Basel). 2021 Feb 05;13(4). doi: 10.3390/cancers13040629. PMID: 33562525; PMCID: PMC7914957.
Copy Download .nbib Format: NLM
Outcome of Relapsed or Refractory .

Cancers

Bertoli S, Dumas PY, Bérard E, Largeaud L, Bidet A, Delabesse E, Tavitian S, Gadaud N, Leguay T, Leroy H, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, Grande AC, Récher C, Pigneux A.
PMID: 32218221
Cancers (Basel). 2020 Mar 25;12(4). doi: 10.3390/cancers12040773.

A recent phase 3 trial showed that the outcome of patients with relapsed/refractory (R/R)

Cite
Bertoli S, Dumas PY, Bérard E, et al. Outcome of Relapsed or Refractory . Cancers (Basel). 2020;12(4)doi: 10.3390/cancers12040773.
Bertoli, S., Dumas, P. Y., Bérard, E., Largeaud, L., Bidet, A., Delabesse, E., Tavitian, S., Gadaud, N., Leguay, T., Leroy, H., Rieu, J. B., Vial, J. P., Vergez, F., Lechevalier, N., Luquet, I., Klein, E., Sarry, A., Grande, A. C., Récher, C., & Pigneux, A. (2020). Outcome of Relapsed or Refractory . Cancers, 12(4), . https://doi.org/10.3390/cancers12040773
Bertoli, Sarah, et al. "Outcome of Relapsed or Refractory ." Cancers vol. 12,4 (2020). doi: https://doi.org/10.3390/cancers12040773
Bertoli S, Dumas PY, Bérard E, Largeaud L, Bidet A, Delabesse E, Tavitian S, Gadaud N, Leguay T, Leroy H, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, Grande AC, Récher C, Pigneux A. Outcome of Relapsed or Refractory . Cancers (Basel). 2020 Mar 25;12(4). doi: 10.3390/cancers12040773. PMID: 32218221; PMCID: PMC7226007.
Copy Download .nbib Format: NLM
Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer.

Translational lung cancer research

Rotolo F, Zhu CQ, Brambilla E, Graziano SL, Olaussen K, Le-Chevalier T, Pignon JP, Kratzke R, Soria JC, Shepherd FA, Seymour L, Michiels S, Tsao MS, Goff B.
PMID: 30050779
Transl Lung Cancer Res. 2018 Jun;7(3):416-427. doi: 10.21037/tlcr.2018.05.01.

BACKGROUND: Adjuvant chemotherapy (ACT) provides modest benefit in resected non-small cell lung cancer (NSCLC) patients. Genome-wide studies have identified gene copy number aberrations (CNA), but their prognostic implication is unknown.METHODS: DNA from 1,013 FFPE tumor samples from three pivotal...

Cite
Rotolo F, Zhu CQ, Brambilla E, et al. Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. Transl Lung Cancer Res. 2018;7(3):416-427doi: 10.21037/tlcr.2018.05.01.
Rotolo, F., Zhu, C. Q., Brambilla, E., Graziano, S. L., Olaussen, K., Le-Chevalier, T., Pignon, J. P., Kratzke, R., Soria, J. C., Shepherd, F. A., Seymour, L., Michiels, S., Tsao, M. S., & Goff, B. (2018). Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. Translational lung cancer research, 7(3), 416-427. https://doi.org/10.21037/tlcr.2018.05.01
Rotolo, Federico, et al. "Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer." Translational lung cancer research vol. 7,3 (2018): 416-427. doi: https://doi.org/10.21037/tlcr.2018.05.01
Rotolo F, Zhu CQ, Brambilla E, Graziano SL, Olaussen K, Le-Chevalier T, Pignon JP, Kratzke R, Soria JC, Shepherd FA, Seymour L, Michiels S, Tsao MS, Goff B. Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. Transl Lung Cancer Res. 2018 Jun;7(3):416-427. doi: 10.21037/tlcr.2018.05.01. PMID: 30050779; PMCID: PMC6037976.
Copy Download .nbib Format: NLM
Innovation in Flow Cytometry Analysis: A New Paradigm Delineating Normal or Diseased Bone Marrow Subsets Through Machine Learning.

HemaSphere

Lacombe F, Dupont B, Lechevalier N, Vial JP, Béné MC.
PMID: 31723814
Hemasphere. 2019 Feb 22;3(2):e173. doi: 10.1097/HS9.0000000000000173. eCollection 2019 Apr.

No abstract available.

Cite
Lacombe F, Dupont B, Lechevalier N, et al. Innovation in Flow Cytometry Analysis: A New Paradigm Delineating Normal or Diseased Bone Marrow Subsets Through Machine Learning. Hemasphere. 2019;3(2):e173doi: 10.1097/HS9.0000000000000173.
Lacombe, F., Dupont, B., Lechevalier, N., Vial, J. P., & Béné, M. C. (2019). Innovation in Flow Cytometry Analysis: A New Paradigm Delineating Normal or Diseased Bone Marrow Subsets Through Machine Learning. HemaSphere, 3(2), e173. https://doi.org/10.1097/HS9.0000000000000173
Lacombe, Francis, et al. "Innovation in Flow Cytometry Analysis: A New Paradigm Delineating Normal or Diseased Bone Marrow Subsets Through Machine Learning." HemaSphere vol. 3,2 (2019): e173. doi: https://doi.org/10.1097/HS9.0000000000000173
Lacombe F, Dupont B, Lechevalier N, Vial JP, Béné MC. Innovation in Flow Cytometry Analysis: A New Paradigm Delineating Normal or Diseased Bone Marrow Subsets Through Machine Learning. Hemasphere. 2019 Feb 22;3(2):e173. doi: 10.1097/HS9.0000000000000173. eCollection 2019 Apr. PMID: 31723814; PMCID: PMC6746040.
Copy Download .nbib Format: NLM
[No title available]

La Revue de medecine interne

N'guyen Van Thanh Dit Bayard J, Glanowski C, Clouzeau A, Bialé L, Banal F, Lechevalier D.
PMID: 30100100
Rev Med Interne. 2018 Oct;39(10):834. doi: 10.1016/j.revmed.2018.07.010. Epub 2018 Aug 09.

No abstract available.

Cite
N'guyen Van Thanh Dit Bayard J, Glanowski C, Clouzeau A, et al. Une sarcoïdose sous tocilizumab : à propos d’un cas. . Rev Med Interne. 2018;39(10):834doi: 10.1016/j.revmed.2018.07.010.
N'guyen Van Thanh Dit Bayard, J., Glanowski, C., Clouzeau, A., Bialé, L., Banal, F., & Lechevalier, D. (2018). Une sarcoïdose sous tocilizumab : à propos d’un cas. . La Revue de medecine interne, 39(10), 834. https://doi.org/10.1016/j.revmed.2018.07.010
N'guyen Van Thanh Dit Bayard, J, et al. "Une sarcoïdose sous tocilizumab : à propos d’un cas." . La Revue de medecine interne vol. 39,10 (2018): 834. doi: https://doi.org/10.1016/j.revmed.2018.07.010
N'guyen Van Thanh Dit Bayard J, Glanowski C, Clouzeau A, Bialé L, Banal F, Lechevalier D. Une sarcoïdose sous tocilizumab : à propos d’un cas. . Rev Med Interne. 2018 Oct;39(10):834. doi: 10.1016/j.revmed.2018.07.010. Epub 2018 Aug 09. French. PMID: 30100100.
Copy Download .nbib Format: NLM
[No dementia or amusia: Maurice Ravel's disease, a singular disease].

La Revue du praticien

Lechevalier B.
PMID: 30869338
Rev Prat. 2018 Sep;68(7):807-809.

No abstract available.

Cite
Lechevalier B. Ni démence ni amusie : la maladie de Maurice Ravel, une maladie singulière. [No dementia or amusia: Maurice Ravel's disease, a singular disease]. Rev Prat. 2018;68(7):807-809
Lechevalier, B. (2018). Ni démence ni amusie : la maladie de Maurice Ravel, une maladie singulière. [No dementia or amusia: Maurice Ravel's disease, a singular disease]. La Revue du praticien, 68(7), 807-809.
Lechevalier, Bernard. "Ni démence ni amusie : la maladie de Maurice Ravel, une maladie singulière." [No dementia or amusia: Maurice Ravel's disease, a singular disease]. La Revue du praticien vol. 68,7 (2018): 807-809.
Lechevalier B. Ni démence ni amusie : la maladie de Maurice Ravel, une maladie singulière. [No dementia or amusia: Maurice Ravel's disease, a singular disease]. Rev Prat. 2018 Sep;68(7):807-809. French. PMID: 30869338.
Copy Download .nbib Format: NLM
Gaussian Process Regression (GPR) Representation in Predictive Model Markup Language (PMML).

Smart and sustainable manufacturing systems

Park J, Lechevalier D, Ak R, Ferguson M, Law KH, Lee YT, Rachuri S.
PMID: 29202125
Smart Sustain Manuf Syst. 2017;1(1):121-141. doi: 10.1520/SSMS20160008. Epub 2017 Mar 29.

This paper describes Gaussian process regression (GPR) models presented in predictive model markup language (PMML). PMML is an extensible-markup-language (XML) -based standard language used to represent data-mining and predictive analytic models, as well as pre- and post-processed data. The...

Cite
Park J, Lechevalier D, Ak R, et al. Gaussian Process Regression (GPR) Representation in Predictive Model Markup Language (PMML). Smart Sustain Manuf Syst. 2017;1(1):121-141doi: 10.1520/SSMS20160008.
Park, J., Lechevalier, D., Ak, R., Ferguson, M., Law, K. H., Lee, Y. T., & Rachuri, S. (2017). Gaussian Process Regression (GPR) Representation in Predictive Model Markup Language (PMML). Smart and sustainable manufacturing systems, 1(1), 121-141. https://doi.org/10.1520/SSMS20160008
Park, J, et al. "Gaussian Process Regression (GPR) Representation in Predictive Model Markup Language (PMML)." Smart and sustainable manufacturing systems vol. 1,1 (2017): 121-141. doi: https://doi.org/10.1520/SSMS20160008
Park J, Lechevalier D, Ak R, Ferguson M, Law KH, Lee YT, Rachuri S. Gaussian Process Regression (GPR) Representation in Predictive Model Markup Language (PMML). Smart Sustain Manuf Syst. 2017;1(1):121-141. doi: 10.1520/SSMS20160008. Epub 2017 Mar 29. PMID: 29202125; PMCID: PMC5705103.
Copy Download .nbib Format: NLM
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.

Oncoimmunology

Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, Ploix S, Vimond N, Peguillet I, Théry C, Lacroix L, Zoernig I, Dhodapkar K, Dhodapkar M, Viaud S, Soria JC, Reiners KS, Pogge von Strandmann E, Vély F, Rusakiewicz S, Eggermont A, Pitt JM, Zitvogel L, Chaput N.
PMID: 27141373
Oncoimmunology. 2015 Aug 12;5(4):e1071008. doi: 10.1080/2162402X.2015.1071008. eCollection 2016 Apr.

Dendritic cell-derived exosomes (Dex) are small extracellular vesicles secreted by viable dendritic cells. In the two phase-I trials that we conducted using the first generation of Dex (IFN-γ-free) in end-stage cancer, we reported that Dex exerted natural killer (NK)...

Cite
Besse B, Charrier M, Lapierre V, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2015;5(4):e1071008doi: 10.1080/2162402X.2015.1071008.
Besse, B., Charrier, M., Lapierre, V., Dansin, E., Lantz, O., Planchard, D., Le Chevalier, T., Livartoski, A., Barlesi, F., Laplanche, A., Ploix, S., Vimond, N., Peguillet, I., Théry, C., Lacroix, L., Zoernig, I., Dhodapkar, K., Dhodapkar, M., Viaud, S., Soria, J. C., Reiners, K. S., Pogge von Strandmann, E., Vély, F., Rusakiewicz, S., Eggermont, A., Pitt, J. M., Zitvogel, L., & Chaput, N. (2016). Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology, 5(4), e1071008. https://doi.org/10.1080/2162402X.2015.1071008
Besse, Benjamin, et al. "Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC." Oncoimmunology vol. 5,4 (2016): e1071008. doi: https://doi.org/10.1080/2162402X.2015.1071008
Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, Ploix S, Vimond N, Peguillet I, Théry C, Lacroix L, Zoernig I, Dhodapkar K, Dhodapkar M, Viaud S, Soria JC, Reiners KS, Pogge von Strandmann E, Vély F, Rusakiewicz S, Eggermont A, Pitt JM, Zitvogel L, Chaput N. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2015 Aug 12;5(4):e1071008. doi: 10.1080/2162402X.2015.1071008. eCollection 2016 Apr. PMID: 27141373; PMCID: PMC4839329.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 44 entries